CL2014002097A1 - Compuestos derivados de tetrahidro-quinazolinona, inhibidores de tank y parp-1; proceso de preparacion; medicamentos; kit farmaceutico; uso en el tratamiento y/o la prevencion de cancer, esclerosis multiple, enfermedades cardiovasculares, lesion del sistema nervioso central. - Google Patents

Compuestos derivados de tetrahidro-quinazolinona, inhibidores de tank y parp-1; proceso de preparacion; medicamentos; kit farmaceutico; uso en el tratamiento y/o la prevencion de cancer, esclerosis multiple, enfermedades cardiovasculares, lesion del sistema nervioso central.

Info

Publication number
CL2014002097A1
CL2014002097A1 CL2014002097A CL2014002097A CL2014002097A1 CL 2014002097 A1 CL2014002097 A1 CL 2014002097A1 CL 2014002097 A CL2014002097 A CL 2014002097A CL 2014002097 A CL2014002097 A CL 2014002097A CL 2014002097 A1 CL2014002097 A1 CL 2014002097A1
Authority
CL
Chile
Prior art keywords
tetrahydroquinazolinone
parp
medicines
inhibitors
cancer
Prior art date
Application number
CL2014002097A
Other languages
English (en)
Inventor
Birgitta Leuthner
Hans-Peter Buchstaller
Christina Esdar
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002097(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CL2014002097A1 publication Critical patent/CL2014002097A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2014002097A 2012-02-09 2014-08-07 Compuestos derivados de tetrahidro-quinazolinona, inhibidores de tank y parp-1; proceso de preparacion; medicamentos; kit farmaceutico; uso en el tratamiento y/o la prevencion de cancer, esclerosis multiple, enfermedades cardiovasculares, lesion del sistema nervioso central. CL2014002097A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12000841 2012-02-09

Publications (1)

Publication Number Publication Date
CL2014002097A1 true CL2014002097A1 (es) 2014-11-07

Family

ID=47628092

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002097A CL2014002097A1 (es) 2012-02-09 2014-08-07 Compuestos derivados de tetrahidro-quinazolinona, inhibidores de tank y parp-1; proceso de preparacion; medicamentos; kit farmaceutico; uso en el tratamiento y/o la prevencion de cancer, esclerosis multiple, enfermedades cardiovasculares, lesion del sistema nervioso central.

Country Status (31)

Country Link
US (1) US9339503B2 (es)
EP (1) EP2812323B1 (es)
JP (1) JP6116592B2 (es)
KR (1) KR20140121477A (es)
CN (1) CN104093714B (es)
AR (1) AR089944A1 (es)
AU (1) AU2013218357B2 (es)
BR (1) BR112014019357A8 (es)
CA (1) CA2863991C (es)
CL (1) CL2014002097A1 (es)
CO (1) CO7020919A2 (es)
DK (1) DK2812323T3 (es)
EA (1) EA026611B1 (es)
EC (1) ECSP14017586A (es)
ES (1) ES2579980T3 (es)
HR (1) HRP20160735T1 (es)
HU (1) HUE029717T2 (es)
IL (1) IL233984A (es)
MX (1) MX349736B (es)
NZ (1) NZ630170A (es)
PE (1) PE20141823A1 (es)
PH (1) PH12014501581B1 (es)
PL (1) PL2812323T3 (es)
PT (1) PT2812323T (es)
RS (1) RS55377B1 (es)
SG (1) SG11201404654SA (es)
SI (1) SI2812323T1 (es)
TW (1) TWI572593B (es)
UA (1) UA116627C2 (es)
WO (1) WO2013117288A1 (es)
ZA (1) ZA201406579B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
EP2890696A1 (en) * 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
DK2938598T3 (en) 2012-12-31 2017-02-13 Cadila Healthcare Ltd Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US9624218B2 (en) 2013-11-07 2017-04-18 Eli Lilly And Company Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors
WO2016192657A1 (en) 2015-06-03 2016-12-08 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use and use thereof
KR101777475B1 (ko) * 2015-12-08 2017-09-11 에스티팜 주식회사 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
EP3480198B1 (en) 2016-06-30 2021-05-05 Riken Novel compound or pharmaceutically acceptable salt thereof
CN108727302A (zh) * 2017-10-23 2018-11-02 科迈化工股份有限公司 一种环保型n-叔丁基-2-苯并噻唑次磺酰胺(ns)合成工艺
US11566017B2 (en) 2017-12-27 2023-01-31 Riken Dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor
JP7369968B2 (ja) * 2017-12-27 2023-10-27 公益財団法人がん研究会 抗がん剤
CR20210083A (es) 2018-08-16 2021-04-19 Hoffmann La Roche Compuestos de anillo fusionado

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
WO2006003150A1 (en) * 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
US8268845B2 (en) 2005-03-11 2012-09-18 Merck Patent Gmbh Tetrahydro- and dihydroquinazolinones
HRP20120346T1 (hr) 2007-03-08 2012-05-31 Janssen Pharmaceutica N.V. Derivati kinolinona kao parp i tank inhibitori
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2011111880A1 (ko) * 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물

Also Published As

Publication number Publication date
ECSP14017586A (es) 2015-09-30
CN104093714B (zh) 2016-08-24
WO2013117288A1 (en) 2013-08-15
UA116627C2 (uk) 2018-04-25
TWI572593B (zh) 2017-03-01
HK1202551A1 (zh) 2015-10-02
HUE029717T2 (en) 2017-03-28
EP2812323A1 (en) 2014-12-17
HRP20160735T1 (hr) 2016-07-29
RS55377B1 (sr) 2017-03-31
IL233984A (en) 2017-09-28
CN104093714A (zh) 2014-10-08
MX2014009491A (es) 2014-08-29
EA026611B1 (ru) 2017-04-28
PE20141823A1 (es) 2014-11-29
MX349736B (es) 2017-08-10
AU2013218357A8 (en) 2015-01-22
US20150025071A1 (en) 2015-01-22
CA2863991A1 (en) 2013-08-15
AU2013218357B2 (en) 2017-01-05
TW201336828A (zh) 2013-09-16
KR20140121477A (ko) 2014-10-15
PL2812323T3 (pl) 2016-09-30
EA201400879A1 (ru) 2015-01-30
SI2812323T1 (sl) 2016-08-31
PH12014501581A1 (en) 2014-10-08
US9339503B2 (en) 2016-05-17
NZ630170A (en) 2016-03-31
ES2579980T3 (es) 2016-08-18
PH12014501581B1 (en) 2014-10-08
EP2812323B1 (en) 2016-04-06
WO2013117288A8 (en) 2014-07-31
AR089944A1 (es) 2014-10-01
DK2812323T3 (en) 2016-05-09
BR112014019357A2 (es) 2017-06-20
ZA201406579B (en) 2015-12-23
JP6116592B2 (ja) 2017-04-19
BR112014019357A8 (pt) 2017-07-11
AU2013218357A1 (en) 2014-09-25
SG11201404654SA (en) 2014-09-26
JP2015506965A (ja) 2015-03-05
PT2812323T (pt) 2016-07-13
CA2863991C (en) 2020-08-11
CO7020919A2 (es) 2014-08-11

Similar Documents

Publication Publication Date Title
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
CL2014000511A1 (es) Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer.
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
CL2014002557A1 (es) Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras.
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
WO2015077503A8 (en) Autotaxin inhibitor compounds
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
HUE053113T2 (hu) Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
MX2014004861A (es) Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
MX366899B (es) Nuevos compuestos.
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
WO2013164061A8 (en) Pyrrolotriazinone derivatives
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
CL2013002003A1 (es) Compuestos derivados de 1, 2, 4-triazolo [4,3-a] quinoxalina, inhibidores de pde2 y/o 10; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para en el trastamiento de enfermedades del snc
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
MX367425B (es) Derivados de 4-carboxamido-isoindolinona como inhibidores selectivos de parp-1.
WO2013117288A8 (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
EP3337482A4 (en) TRANSDERMAL FORMULATIONS FOR THE DISTRIBUTION OF BERBERIN COMPOUNDS AND THEIR USE IN THE TREATMENT OF BERBER INDEPENDENT ILLNESSES AND DISORDERS
CL2014001959A1 (es) Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer.
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer